Comments
Shares of Lupin today gained over 3 per cent as brokers have upgraded the stock citing higher sales from key drugs.
The shares surged 3.3 per cent adding to Wednesday’s 2.7 per cent rise.
Credit Suisse has upgraded the stock to “outperform’’ from “neutral’’ citing upside from the anti-diabetes generic drugs Fortamet and Glumetza.
Lupin has taken 200 per cent price increase in Fortamet, it said.
Nomura had upgraded Lupin stock to “buy’’ from “neutral’’ on Tuesday.
HSBC had also upgraded the stock to “buy’’ from “hold’’ last week.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.